(NASDAQ: FBLG) Fibrobiologics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41%.
Fibrobiologics's earnings in 2025 is -$13,223,000.On average, 6 Wall Street analysts forecast FBLG's earnings for 2025 to be -$19,549,663, with the lowest FBLG earnings forecast at -$19,704,652, and the highest FBLG earnings forecast at -$18,473,112. On average, 6 Wall Street analysts forecast FBLG's earnings for 2026 to be -$18,054,220, with the lowest FBLG earnings forecast at -$24,220,302, and the highest FBLG earnings forecast at -$13,634,916.
In 2027, FBLG is forecast to generate -$14,313,520 in earnings, with the lowest earnings forecast at -$33,251,601 and the highest earnings forecast at $13,634,916.